Gyrolab platform for optimized product characterization during rAAV manufacturing process

As a CDMO specializing in rAAV vector production, Viralgen is continuously improving the quality control processes to ensure the best product quality.

The Gyrolab platform and associated AAVX Titer and HEK293 HCP detection kits have allowed us to improve the quality of our analytical results within a standardized process, obtaining accurate data in less time and reducing the volume of reagents and samples required for each test.

Andrea received her PhD in Neuroscience from the University of the Basque Country focused on cannabinoid receptors and the ABHD6 enzyme as therapeutic targets in demyelinating diseases such as MS. She then joined Viralgen Vector Core focused in the field of Gene Therapy. She is a member of the Quality Control (QC) in Research and Development department, focused on the QC analysis of recombinant Adeno-Associated Virus (rAAV) Production.

If you have problems viewing the webinar, please contact maritha.lundin@gyrosproteintech.com